SLBT (SL Science Holding) Ending Cash Position: $1.26 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLBT SL Science Holding Ltd SLBT
12 GF Score
Price $3.29
! 3 Warning Signs
View Full Analysis

What is SL Science Holding Ending Cash Position?

SL Science Holding SLBT +24.39% 12 Ending Cash Position is $1.26 Mil as of Dec. 2025. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

SL Science Holding's Ending Cash Position for the quarter that ended in Dec. 2025 was $1.26 Mil.

SL Science Holding's quarterly Ending Cash Position declined from Dec. 2024 ($4.14 Mil) to Jun. 2025 ($3.55 Mil) and declined from Jun. 2025 ($3.55 Mil) to Dec. 2025 ($1.26 Mil).

SL Science Holding's annual Ending Cash Position increased from Dec. 2023 ($0.44 Mil) to Dec. 2024 ($4.14 Mil) but then declined from Dec. 2024 ($4.14 Mil) to Dec. 2025 ($1.26 Mil).

SL Science Holding Ending Cash Position Related Terms

SL Science Holding Ending Cash Position Historical Data

* Premium members only.

The historical data trend for SL Science Holding's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SL Science Holding Ending Cash Position Chart

SL Science Holding Annual Data
Trend Dec23 Dec24 Dec25
Ending Cash Position
0.44 4.14 1.26

SL Science Holding Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position 0.00 6.87 4.14 3.55 1.26
SLBT
12GF Score
SL Science Holding Ltd SLBT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SL Science Holding Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

SL Science Holding's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=4.138+-2.879
=1.26

SL Science Holding's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3.546+-2.287
=1.26

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1.26 Mil mean?
SL Science Holding (SLBT) has a Ending Cash Position of $1.26 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SL Science Holding and its competitors.
Is SL Science Holding's Ending Cash Position too high?
SL Science Holding's current Ending Cash Position is $1.26 Mil. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's Ending Cash Position compare to DMRA and BCAX?
SL Science Holding's Ending Cash Position of $1.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on SL Science Holding and its competitors. SL Science Holding's current Ending Cash Position is $1.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current Ending Cash Position of $1.26 Mil. The current Ending Cash Position is $1.26 Mil. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For SL Science Holding (SLBT), the current Ending Cash Position is $1.26 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SL Science Holding Business Description

Address No. 479 Chongyang Road, 11th Floor, Nangang District, Taipei, TWN, 115010
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score

Get the complete analysis for SLBT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price